Page 136 - Haematologica Vol. 110 - January 2025

ARTICLE - CITE-seq analysis of HU effects on CML cells
H. Komic et al.
multimodal single-cell data. Cell. 2021;184(13):3573-3587.
21. Gutiérrez L, Caballero N, Fernández-Calleja L, Karkoulia E, Strouboulis J. Regulation of GATA1 levels in erythropoiesis.
IUBMB Life. 2020;72(1):89-105.
22. Buscemi G, Carlessi L, Zannini L, et al. DNA damage-induced
cell cycle regulation and function of novel Chk2
phosphoresidues. Mol Cell Biol. 2006;26(21):7832-7845.
23. Warfvinge R, Geironson L, Sommarin MNE, et al. Single-cell
molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384-2394.
24. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117(6):1113-1122.
25. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120(7):1390-1397.
26. Gui CY, Jiang C, Qian RL. [The role of hydroxyurea in globin gene expression and cell differentiation of human erythroleukemia cell line]. Shi Yan Sheng Wu Xue Bao. 1997;30(4):375-382.
27. Krishnan V, Schmidt F, Nawaz Z, et al. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023;141(22):2738-2755.
28. Kapor S, Vukotić M, Subotički T, et al. Hydroxyurea induces
bone marrow mesenchymal stromal cells senescence and
modifies cell functionality in vitro. J Pers Med. 2021;11(11):1048. 29. Apraiz A, Mitxelena J, Zubiaga A. Studying cell cycle-regulated
gene expression by two complementary cell synchronization
protocols. J Vis Exp. 2017;(124):55745.
30. Behbehani GK, Samusik N, Bjornson ZB, Fantl WJ, Medeiros BC,
Nolan GP. Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy. Cancer Discov. 2015;5(9):988-1003.
31. Rinaldi I, Reksodiputro AH, Jusman SW, et al. Longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic- phase chronic myeloid leukemia: possibility of P-glycoprotein role. Asian Pac J Cancer Prev. 2019;20(12):3689-3695.
32. Lange T, Niederwieser C, Gil A, et al. No advantage of imatinib in combination with hydroxyurea over imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML Study Group. Leuk Lymphoma. 2020;61(12):2821-2830.
33. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96(9):3195-3199.
Haematologica | 110 January 2025
128